MedDataX Logo

Muscle Parameters and Pathological Response in Breast Cancer Patients

NCT ID: NCT06151379

Last Updated: 2023-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

69 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2023-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoadjuvant Chemotherapy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

operable breast cancer skeletal mass index neoadjuvant chemotherapy pathologic response L3 vertebra

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pathologic complete response (pCR)

Patient with complete pathological response

Neoadjuvant therapy

Intervention Type OTHER

To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Pathologic incomplete response (non-pCR)

Patient with partial pathological response

Neoadjuvant therapy

Intervention Type OTHER

To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neoadjuvant therapy

To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.

Exclusion Criteria

* Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.
Minimum Eligible Age

29 Years

Maximum Eligible Age

72 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Acıbadem Atunizade Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ebru Yilmaz

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aysun Isiklar, M.D.

Role: PRINCIPAL_INVESTIGATOR

Acıbadem Atunizade Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AcıbademAH

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AcıbademAH

Identifier Type: -

Identifier Source: org_study_id